{"id":"NCT02235909","sponsor":"Arbor Pharmaceuticals, Inc.","briefTitle":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","officialTitle":"A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-30","primaryCompletion":"2019-11-11","completion":"2019-11-11","firstPosted":"2014-09-10","resultsPosted":"2025-02-25","lastUpdate":"2025-02-25"},"enrollment":377,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan Medoxomil Low-dose","otherNames":["AR14","AZM-L"]},{"type":"DRUG","name":"Losartan","otherNames":["Cozaar"]},{"type":"DRUG","name":"Placebo for Azilsartan Medoxomil","otherNames":[]},{"type":"DRUG","name":"Placebo for Losartan","otherNames":[]},{"type":"DRUG","name":"Azilsartan Medoxomil Medium-dose (20 mg)","otherNames":["AR14","AZM-M"]},{"type":"DRUG","name":"Azilsartan Medoxomil High-dose (40 mg)","otherNames":["AR14","AZM-H"]}],"arms":[{"label":"Double-blind: Azilsartan Medoxomil - Low dose","type":"EXPERIMENTAL"},{"label":"Double blind phase: Losartan","type":"ACTIVE_COMPARATOR"},{"label":"Withdrawal Phase: Azilsartan medoxomil low-dose (AZM-L)","type":"ACTIVE_COMPARATOR"},{"label":"Withdrawal Phase: Placebo to match azilsartan medoxomil low dose (AZM-L)","type":"PLACEBO_COMPARATOR"},{"label":"Open Label Phase: Azilsartan Medoxomil","type":"EXPERIMENTAL"},{"label":"Withdrawal Phase: Losartan 50 mg","type":"ACTIVE_COMPARATOR"},{"label":"Withdrawal Phase: Placebo to Losartan","type":"PLACEBO_COMPARATOR"},{"label":"Double-blind: Azilsartan Medoxomil - Medium dose","type":"EXPERIMENTAL"},{"label":"Double-blind: Azilsartan Medoxomil - High dose (AZM-H)","type":"EXPERIMENTAL"},{"label":"Withdrawal: Azilsartan Medoxomil - Medium dose","type":"EXPERIMENTAL"},{"label":"Withdrawal: Azilsartan Medoxomil - High dose","type":"EXPERIMENTAL"},{"label":"Withdrawal Phase: Placebo to match azilsartan medoxomil medium dose (AZM-M)","type":"EXPERIMENTAL"},{"label":"Withdrawal Phase: Placebo to match azilsartan medoxomil high dose (AZM-H)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which is in the same class of drug and is approved for use in the pediatric population aged 6 years and older. Approximately 260 subjects will participate in a 6-week, double-blind, randomized, treatment phase, followed by a 2-week, double-blind, randomized, placebo-controlled withdrawal phase. A 44-week, open-label extension in which all subjects will receive azilsartan and other antihypertensive medications (if needed). Blood pressure will be assessed throughout the study.","primaryOutcome":{"measure":"Change in Seated Diastolic Blood Pressure Between AZM and Placebo","timeFrame":"From Week 6/Final Visit of DB Phase to Week 8/Final Visit of Withdrawal Phase","effectByArm":[{"arm":"Pooled Placebo","deltaMin":3.9,"sd":8},{"arm":"Pooled AZM","deltaMin":-1.6,"sd":6.69}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":69,"countries":["United States","Argentina","Brazil","Bulgaria","Colombia","Hungary","Italy","Mexico","Poland","South Africa","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":289},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Gastroenteritis"]}}